Aerovate Therapeutics Inc Cash Flow-to-Debt Ratio
Aerovate Therapeutics Inc cash flow-to-debt ratio. Aerovate Therapeutics Inc (AVTE) has a Cash Flow-to-Debt Ratio of -0.96x as of March 2025, meaning its operating cash flow of $-2.38 Million could theoretically repay -1% of its total liabilities ($2.49 Million) in one year. See financial agility of Aerovate Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Aerovate Therapeutics Inc (2019–2024)
Cash flow-to-debt ratio of Aerovate Therapeutics Inc from 2019 to 2024. Historical debt coverage capacity for Aerovate Therapeutics Inc across 6 annual periods. Also explore AVTE net asset momentum to track the company's year-over-year net asset growth rate.
Aerovate Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2019–2024)
Aerovate Therapeutics Inc cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for Aerovate Therapeutics Inc. For the full cash flow conversion analysis, see AVTE cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -18.26x | $-71.20 Million | $3.90 Million | ▼ -477.8% |
| 2023 | -3.16x | $-56.78 Million | $17.96 Million | ▲ +30.9% |
| 2022 | -4.57x | $-39.12 Million | $8.56 Million | ▲ +50.9% |
| 2021 | -9.30x | $-27.40 Million | $2.94 Million | ▼ -2037.8% |
| 2020 | -0.44x | $-7.86 Million | $18.06 Million | ▼ -12.0% |
| 2019 | -0.39x | $-2.78 Million | $7.16 Million | — |